Recombinant IGFBP-3 inhibits allergic lung inflammation, VEGF production, and vascular leak in a mouse model of asthma

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 7, 2012, Pages 869-877

  Kim, S R ^a   Lee, K S ^a   Lee, K B ^a   Lee, Yong C ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

Allergic airway disease; HIF ; IGFBP 3; Vascular endothelial growth factor; Vascular permeability

Indexed keywords

ALLERGEN; CBO P11; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; OVALBUMIN; RINFABATE; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; BLOOD VESSEL PERMEABILITY; DISEASE MODEL; FEMALE; INFLAMMATORY CELL; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY EFFECT;

ANIMALS; ASTHMA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRONCHOALVEOLAR LAVAGE FLUID; CAPILLARY PERMEABILITY; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTHELIAL GROWTH FACTORS; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOGLOBULIN E; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, INBRED C57BL; OVALBUMIN; PEPTIDES, CYCLIC; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PNEUMONIA; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS; TH2 CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862026386     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2012.02837.x     Document Type: Article

References (35)

1. Kanazawa H, Asai K, Hirata K, Yoshikawa J. Vascular involvement in exercise-induced airway narrowing in patients with bronchial asthma. Chest 2002;122:166-170. (Pubitemid 34754157)
2. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-1039.
3. Lee KS, Kim SR, Park HS, Jin GY, Lee YC. Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expression. J Allergy Clin Immunol 2004;114:1093-1099. (Pubitemid 39469149)
4. Bilton RL, Booker GW. The subtle side to hypoxia-inducible factor (HIFα) regulation. Eur J Biochem 2003;270:791-798. (Pubitemid 36315322)
5. Semenza GL. Expression of hypoxia inducible factor 1: mechanisms and consequences. Biochem Pharmacol 1999;59:47-53.
6. Qing G, Simon MC. Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev 2009;19:60-66.
7. Gruber M, Simon MC. Hypoxia-inducible factors, hypoxia, and tumor angiogenesis. Curr Opin Hematol 2006;13:169-174.
8. Kim SR, Lee KS, Park HS, Park SJ, Min KH, Jin SM et al. HIF-1α inhibition ameliorates an allergic airway disease via VEGF suppression in bronchial epithelium. Eur J Immunol 2010;40:2858-2869.
9. LeRoith D, Werner H, Burguera B, Roberts CT Jr, Mulroney S, Haramati A. The insulin-like growth factor family of peptides, binding proteins and receptors: their potential role in tissue regeneration. Adv Exp Med Biol 1992;321:21-28; discussion 29-30.
10. Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev 2009;30:417-437.
11. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
12. Fu P, Thompson JA, Bach LA. Promotion of cancer cell migration: an insulin-like growth factor (IGF)-independent action of IGF-binding protein-6. J Biol Chem 2007;282:22298-22306. (Pubitemid 47267353)
13. Yamashita N, Tashimo H, Ishida H, Matsuo Y, Arai H, Nagase H et al. Role of insulin-like growth factor-I in allergen-induced airway inflammation and remodeling. Cell Immunol 2005;235:85-91. (Pubitemid 41597471)
14. Hoshino M, Nakamura Y, Sim JJ, Yamashiro Y, Uchida K, Hosaka K et al. Inhaled corticosteroid reduced lamina reticularis of the basement membrane by modulation of insulin-like growth factor (IGF)-I expression in bronchial asthma. Clin Exp Allergy 1998;28:568-577. (Pubitemid 28238271)
15. Lee YC, Jogie-Brahim S, Lee DY, Han J, Harada A, Murphy LJ et al. Insulin-like growth factor-binding protein-3 (IGFBP-3) blocks the effects of asthma by negatively regulating NF-jB signaling through IGFBP-3R-mediated activation of caspases. J Biol Chem 2011;286:17898-17909.
16. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002;277:38205-38211. (Pubitemid 35154674)
17. Miele C, Rochford JJ, Filippa N, Giorgetti-Peraldi S, Van Obberghen E. Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem 2000;275:21695-21702. (Pubitemid 30481878)
18. Lee KS, Kim SR, Park SJ, Park HS, Min KH, Jin SM et al. PPARγ modulates reactive oxygen species generation and activation of NF-κB and HIF-1α in allergic airway disease of mice. J Allergy Clin Immunol 2006;118:120-127.
19. Kwak YG, Song CH, Yi HK, Hwang PH, Kim JS, Lee KS et al. Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J Clin Invest 2003;111:1083-1092. (Pubitemid 36397485)
20. Zilberberg L, Shinkaruk S, Lequin O, Rousseau B, Hagedorn M, Costa F et al. Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. J Biol Chem 2003;278:35564-35573. (Pubitemid 37102329)
21. Tournoy KG, Kips JC, Schou C, Pauwels RA. Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsiveness. Clin Exp Allergy 2000;30:79-85. (Pubitemid 30093884)
22. Takeda K, Hamelmann E, Joetham A, Shultz LD, Larson GL, Irvin CG et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J Exp Med 1997;186:449-454. (Pubitemid 27332903)
23. Martin JL, Coverley JA, Pattison ST, Baxter RC. Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology 1995;136:1219-1226.
24. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM et al. Direct functional interactions between insulin-like growth factor binding protein-3 and retinoid X receptor regulate transcriptional signaling and apoptosis. J Biol Chem 2000;275:33607-33613.
25. Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y et al. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 2007;26:1811-1819. (Pubitemid 46426204)
26. Punglia RS, Lu M, Hsu J, Kuroki M, Tolentino MJ, Keough K et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 1997;46:1619-1626. (Pubitemid 27411239)
27. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460-463. (Pubitemid 30208166)
28. H2-mediated sensitization and inflammation in the lung. Nat Med 2004;10:1095-1103.
29. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-1237.
30. Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Differ 2008;15:621-627.
31. Elson DA, Ryan HE, Snow JW, Johnson R, Arbeit JM. Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. Cancer Res 2000;60:6189-6195.
32. Imamura T, Kikuchi H, Herraiz MT, Park DY, Mizukami Y, Mino-Kenduson M et al. HIF-1alpha and HIF-2alpha have divergent roles in colon cancer. Int J Cancer 2009;124:763-771.
33. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008;14:435-446.
34. Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN et al. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12:653-661. (Pubitemid 43166161)
35. Franklin SL, Ferry RJ Jr, Cohen P. Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. J Clin Endocrinol Metab 2003;88:900-907. (Pubitemid 36207840)